DK0781092T3 - Nucleinsyre som koder for adenovirus E1A-polypeptid til sensibilisering af tumorceller for kemoterapi eller bestråling - Google Patents

Nucleinsyre som koder for adenovirus E1A-polypeptid til sensibilisering af tumorceller for kemoterapi eller bestråling

Info

Publication number
DK0781092T3
DK0781092T3 DK95933746T DK95933746T DK0781092T3 DK 0781092 T3 DK0781092 T3 DK 0781092T3 DK 95933746 T DK95933746 T DK 95933746T DK 95933746 T DK95933746 T DK 95933746T DK 0781092 T3 DK0781092 T3 DK 0781092T3
Authority
DK
Denmark
Prior art keywords
polypeptide
nucleic acid
acid encoding
chemotherapy
tumor cell
Prior art date
Application number
DK95933746T
Other languages
English (en)
Inventor
Steven M Frisch
Original Assignee
Jolla Cancer Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jolla Cancer Res Found filed Critical Jolla Cancer Res Found
Application granted granted Critical
Publication of DK0781092T3 publication Critical patent/DK0781092T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95933746T 1994-09-06 1995-09-05 Nucleinsyre som koder for adenovirus E1A-polypeptid til sensibilisering af tumorceller for kemoterapi eller bestråling DK0781092T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/301,316 US5776743A (en) 1994-09-06 1994-09-06 Method of sensitizing tumor cells with adenovirus E1A
PCT/US1995/011342 WO1996007322A1 (en) 1994-09-06 1995-09-05 Method of sensitizing tumor cells with adenovirus e1a

Publications (1)

Publication Number Publication Date
DK0781092T3 true DK0781092T3 (da) 2004-08-30

Family

ID=23162849

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95933746T DK0781092T3 (da) 1994-09-06 1995-09-05 Nucleinsyre som koder for adenovirus E1A-polypeptid til sensibilisering af tumorceller for kemoterapi eller bestråling

Country Status (10)

Country Link
US (3) US5776743A (da)
EP (1) EP0781092B1 (da)
JP (1) JP2000510435A (da)
AT (1) ATE266425T1 (da)
CA (1) CA2199265A1 (da)
DE (1) DE69533036T2 (da)
DK (1) DK0781092T3 (da)
ES (1) ES2216018T3 (da)
PT (1) PT781092E (da)
WO (1) WO1996007322A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776743A (en) * 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
AU733737B2 (en) 1996-03-20 2001-05-24 Board Of Regents, The University Of Texas System Sensitization of her-2/neu overexpressing cancer cells to chemotherapy
US6248351B1 (en) 1997-01-10 2001-06-19 Board Of Regents,The University Of Texas System Human PEA3 is a tumor suppressor for cancer cells
US5922688A (en) 1997-01-10 1999-07-13 Board Of Regents, The University Of Texas System PEA3 is a tumor suppressor
US20040048821A1 (en) * 1997-06-27 2004-03-11 Cold Spring Harbor Laboratory Enhancement of drug cytotoxicity in tumor cells containing mutant Rb gene
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US6911200B2 (en) * 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
PL363618A1 (en) 2000-11-09 2004-11-29 Neopharm, Inc. Sn-38 lipid complexes and methods of use
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
AU2002252160A1 (en) * 2001-03-01 2002-09-19 Northwest Biotherapeutics, Inc. Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
FR2821748A1 (fr) * 2001-03-12 2002-09-13 Laurent Schwartz Utilisation d'un principe actif anti-fibrose pour la preparation d'un medicamment destine a la prevention du cancer broncho-pulmonaire
US20020169126A1 (en) * 2001-03-21 2002-11-14 Mien-Chie Hung Compositions and methods for inactivating the Akt oncogene and/or activating the p38 pro-apoptotic gene
US20030138405A1 (en) * 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US20060147420A1 (en) * 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
NZ536062A (en) * 2002-05-10 2008-03-28 Oncolytics Biotech Inc Sensitization of neoplastic cells to radiation therapy with oncolytic viruses
ES2358730T3 (es) 2002-07-15 2011-05-13 Board Of Regents, The University Of Texas System Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20040191761A1 (en) * 2003-03-27 2004-09-30 Routes John M. Modified adenoviral E1A constructs and methods of use thereof
FR2858460B1 (fr) * 2003-07-30 2005-10-14 Soitec Silicon On Insulator Structure semiconducteur-sur-isolant contrainte ayant une tenue des contraintes aux hautes temperatures
US7879545B2 (en) * 2003-11-05 2011-02-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Identification of novel targets for radio sensitization using a genomic-based radiation sensitivity classifier
CA3031283A1 (en) 2004-01-22 2005-08-04 University Of Miami Topical co-enzyme q10 formulations and methods of use
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
ES2551306T3 (es) * 2006-02-13 2015-11-17 Oncolytics Biotech Inc. Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica
EP2136831B1 (en) 2007-03-02 2012-09-12 The Cleveland Clinic Foundation Anti-angiogenic peptides
US20080234946A1 (en) 2007-03-22 2008-09-25 University Of South Florida Predictive radiosensitivity network model
US20090076734A1 (en) 2007-03-22 2009-03-19 Torres-Roca Javier F Gene Signature for the Prediction of Radiation Therapy Response
JP5580043B2 (ja) * 2007-04-27 2014-08-27 オンコリスバイオファーマ株式会社 放射線増感増強剤
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US8112237B2 (en) * 2009-03-11 2012-02-07 Progress Rail Services Corp. System and method for correcting signal polarities and detection thresholds in a rail vehicle inspection system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504671A (ja) * 1990-12-04 1994-06-02 ボード・オヴ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム Ｎｅｕを介して起こるトランスフォーメーションの抑制方法とそのための組成物
US5516631A (en) 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
DE69417734T2 (de) * 1993-02-16 1999-10-07 Onyx Pharma Inc Cytopathische viren zur therapie und prophylaxe der neoplasie
US5821733A (en) * 1994-02-22 1998-10-13 Packard Bell Nec Multiple cell and serially connected rechargeable batteries and charging system
US5776743A (en) * 1994-09-06 1998-07-07 La Jolla Cancer Research Foundation Method of sensitizing tumor cells with adenovirus E1A

Also Published As

Publication number Publication date
ES2216018T3 (es) 2004-10-16
US6100243A (en) 2000-08-08
PT781092E (pt) 2004-09-30
JP2000510435A (ja) 2000-08-15
DE69533036T2 (de) 2005-05-19
EP0781092A4 (en) 1998-09-30
ATE266425T1 (de) 2004-05-15
US5776743A (en) 1998-07-07
CA2199265A1 (en) 1996-03-14
AU3627895A (en) 1996-03-27
DE69533036D1 (de) 2004-06-17
AU693604B2 (en) 1998-07-02
US6544955B1 (en) 2003-04-08
WO1996007322A1 (en) 1996-03-14
EP0781092A1 (en) 1997-07-02
EP0781092B1 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
DK0781092T3 (da) Nucleinsyre som koder for adenovirus E1A-polypeptid til sensibilisering af tumorceller for kemoterapi eller bestråling
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
Sutherland et al. p‐Aminobenzoic acid can sensitize the formation of pyrimidine dimers in DNA: direct chemical evidence
DE3376524D1 (en) Skin treatment composition
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
DE3376295D1 (en) Pharmaceutical composition containing adenosine derivatives for use in treating tumours
SE8402098D0 (sv) Perfluorkarbonemulsion, framstellning derav samt dess anvendning i terapi
SE8300320L (sv) Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning
DK314586A (da) Monoklonale antistoffer og antigener for humane lungecarcinomer, der ikke er af typen med smaa celler
NO330924B1 (no) Isolert antistoff eller antistoffragment, immunokonjugat, anvendelse av et immunokonjugat, en terapeutisk effektiv mengde av et immunokonjugat eller et antistoff eller antistoffragment for fremstilling av preparater henholdsvis for selektiv odeleggelse av celler, behandling av en sykdomstilstand eller diagnostisering av metastaser eller prostatakreft, samt pavisningsmetode.
AR039997A1 (es) Sensibilizacion de celulas neoplasicas con virus oncoliticos para las terapias con radiacion
DE69815840D1 (de) Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren
NO167047C (no) Katode til bruk i hydrogenutviklende elektrokjemiske prosesser, samt fremgangsmaate til fremstilling av katoden.
DE69903559T2 (de) Verwendung von neuen zelltod inducierenden mitteln im synergismus mit interferon
NZ502800A (en) The use of apoptin in determining the transforming capability of tumorigenic or tumor promoting agents
ATE40116T1 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
IT8223777V0 (it) Struttura riflettente a pannelli accoppiati, atta a delimitare una zona con elevata concentrazione di raggi solari, a scopo abbronzante o terapeutico.
Arai et al. Troponin, tropomyosin, and the relaxing protein; Myofibrilar proteins of rabbit skeletal muscle
Mester et al. Experimental imunological study with radiological application of low power laser
AU6560886A (en) DNA sequence containing the DNA sequence coding for human tissue plasminogen activator originating from human normal cells, recombinant DNA incorporating the DNA sequence, host cells transformed with the recombinant DNA, and process for producing human tissue plasminogen activator by use of the host cells
EP0136093A3 (en) Anti-cancer factors
Reboud et al. Identification of the proteins interacting with tRNA in rat liver small ribosomal subunits
Hamazaki Effect of adenosine 3', 5'-monophosphate on thymidine kinase in tumor cells
Kaufman et al. Use of lactate dehydrogenase as a marker in rat-mouse chimera studies